Logo image of VLON

VALLON PHARMACEUTICALS INC (VLON) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VLON - US92023M1018 - Common Stock

0.4 USD
-0.06 (-13.04%)
Last: 4/21/2023, 8:04:53 PM
0.3901 USD
-0.01 (-2.48%)
After Hours: 4/21/2023, 8:04:53 PM
Fundamental Rating

2

Taking everything into account, VLON scores 2 out of 10 in our fundamental rating. VLON was compared to 191 industry peers in the Pharmaceuticals industry. While VLON seems to be doing ok healthwise, there are quite some concerns on its profitability. VLON is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VLON has reported negative net income.
VLON had a negative operating cash flow in the past year.
VLON had negative earnings in each of the past 5 years.
VLON had a negative operating cash flow in each of the past 5 years.
VLON Yearly Net Income VS EBIT VS OCF VS FCFVLON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -2M -4M -6M -8M

1.2 Ratios

VLON has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VLON Yearly ROA, ROE, ROICVLON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VLON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VLON Yearly Profit, Operating, Gross MarginsVLON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for VLON has been increased compared to 1 year ago.
VLON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VLON Yearly Shares OutstandingVLON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
VLON Yearly Total Debt VS Total AssetsVLON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2M 4M 6M 8M

2.2 Solvency

VLON has an Altman-Z score of -12.80. This is a bad value and indicates that VLON is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VLON (-12.80) is worse than 82.65% of its industry peers.
There is no outstanding debt for VLON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.8
ROIC/WACCN/A
WACCN/A
VLON Yearly LT Debt VS Equity VS FCFVLON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 5M -5M

2.3 Liquidity

VLON has a Current Ratio of 2.29. This indicates that VLON is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VLON (2.29) is worse than 62.56% of its industry peers.
A Quick Ratio of 2.29 indicates that VLON has no problem at all paying its short term obligations.
With a Quick ratio value of 2.29, VLON perfoms like the industry average, outperforming 43.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.29
VLON Yearly Current Assets VS Current LiabilitesVLON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

VLON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.46%, which is quite impressive.
EPS 1Y (TTM)44.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VLON Yearly Revenue VS EstimatesVLON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 20K 40K 60K 80K
VLON Yearly EPS VS EstimatesVLON Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VLON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLON Price Earnings VS Forward Price EarningsVLON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLON Per share dataVLON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VLON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALLON PHARMACEUTICALS INC

NASDAQ:VLON (4/21/2023, 8:04:53 PM)

After market: 0.3901 -0.01 (-2.48%)

0.4

-0.06 (-13.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2023-02-13/bmo
Earnings (Next)05-08 2023-05-08/bmo
Inst Owners0.48%
Inst Owner Change-38.03%
Ins Owners8.38%
Ins Owner Change0%
Market Cap5.39M
Revenue(TTM)N/A
Net Income(TTM)-7.02M
Analysts82.86
Price Target12.24 (2960%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.29
Altman-Z -12.8
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.16%
OCF growth 3YN/A
OCF growth 5YN/A

VALLON PHARMACEUTICALS INC / VLON FAQ

What is the fundamental rating for VLON stock?

ChartMill assigns a fundamental rating of 1 / 10 to VLON.


What is the valuation status of VALLON PHARMACEUTICALS INC (VLON) stock?

ChartMill assigns a valuation rating of 1 / 10 to VALLON PHARMACEUTICALS INC (VLON). This can be considered as Overvalued.


Can you provide the profitability details for VALLON PHARMACEUTICALS INC?

VALLON PHARMACEUTICALS INC (VLON) has a profitability rating of 0 / 10.